Antengene study finds ATG-037 and selinexor cut myeloma tumor growth 62%
AI Summary- Antengene reported a preclinical study combining ATG-037 and selinexor in multiple myeloma.
- Combination therapy achieved 62% tumor-growth inhibition in J558-inoculated BALB/c mice.
- Cancer Gene Therapy published the study conducted with Peking University Third Hospital researchers.